AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22036862 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemoporfin 2.5 mg/kg
Number of subjects: 36
Study 22036862 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemoporfin 5 mg/kg
Number of subjects: 36
Study 22036862 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemoporfin 7.5 mg/kg
Number of subjects: 36
Study 22036862 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemoporfin 10 mg/kg
Number of subjects: 36
Study 20053235 — intervention group
Group type: EXPERIMENTAL
Intervention: ACASI-based feedback on reported HIV risk behaviors
Number of subjects: 566
Study 20053235 — intervention group
Group type: COMPARATOR
Intervention: No intervention (no feedback)
Number of subjects: 566
Study 20053235 — intervention group
Group type: EXPERIMENTAL
Intervention: ACASI-based feedback
Number of subjects: 566
Study 17176456 — intervention group
Group type: EXPERIMENTAL
Intervention: Metadoxine (MET)
Number of subjects: 160
Study 17176456 — intervention group
Group type: COMPARATOR
Intervention: NULL (no drug treatment)
Number of subjects: 160
Study 15630643 — intervention group
Group type: EXPERIMENTAL
Intervention: Incisional bupivacaine (0.5 ml/kg, 0.25% for <40 kg, 0.5% for >40 kg)
Number of subjects: 68
Study 15630643 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 15630643 — intervention group
Group type: EXPERIMENTAL
Intervention: Incisional bupivacaine
Number of subjects: 68
Study 10783565 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine mouthrinse (Corsodyl, CHX)
Number of subjects: 12
Study 10783565 — intervention group
Group type: COMPARATOR
Intervention: Commercially available dentifrice supplementing fluoride (Odol‐med‐3)
Number of subjects: 12
Study 8977510 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastine nasal spray (1 puff)
Number of subjects: 20
Study 8977510 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 1600983 — intervention group
Group type: EXPERIMENTAL
Intervention: 175 ms rate responsive AVD
Number of subjects: 10
Study 1600983 — intervention group
Group type: EXPERIMENTAL
Intervention: 125 ms fixed AVD
Number of subjects: 10
Study 1600983 — intervention group
Group type: COMPARATOR
Intervention: 250 ms fixed AVD
Number of subjects: 10
Study 1600983 — intervention group
Group type: EXPERIMENTAL
Intervention: 125 ms AVD
Number of subjects: 10
Study 1600983 — intervention group
Group type: COMPARATOR
Intervention: 250 ms AVD
Number of subjects: 10
Study 3912182 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg felodipine three times a day
Number of subjects: 13
Study 3912182 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg felodipine three times a day
Number of subjects: 13
Study 3912182 — intervention group
Group type: COMPARATOR
Intervention: Placebo (5 mg)
Number of subjects: 13
Study 3912182 — intervention group
Group type: COMPARATOR
Intervention: Placebo (10 mg)
Number of subjects: 13
Study 29502880 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia (cooling to 33.5°C for 72 hours)
Number of subjects: 303
Study 29502880 — intervention group
Group type: COMPARATOR
Intervention: Normothermia
Number of subjects: 303
Study 24496044 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnenolone (50 mg/d)
Number of subjects: 60
Study 24496044 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 25115616 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (400mg/d; n=26)
Number of subjects: 53
Study 25115616 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo (control; n=27)
Number of subjects: 53
Study 23123107 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV13+TIV
Number of subjects: 0
Study 23123107 — intervention group
Group type: COMPARATOR
Intervention: PCV13
Number of subjects: 0
Study 21154012 — intervention group
Group type: EXPERIMENTAL
Intervention: Induced belief that failure was beyond control and unlikely to change (Experiment 1)
Number of subjects: 80
Study 21154012 — intervention group
Group type: EXPERIMENTAL
Intervention: Induced belief that failure was within one's control and likely to change (Experiment 2)
Number of subjects: 80
Study 21154012 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediation by self-efficacy
Number of subjects: 80
Study 18201683 — intervention group
Group type: EXPERIMENTAL
Intervention: AquaLase
Number of subjects: 50
Study 18201683 — intervention group
Group type: COMPARATOR
Intervention: NeoSoniX
Number of subjects: 50
Study 16645372 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibutilide pretreatment (0.01 mg/kg IV over 10 min)
Number of subjects: 50
Study 16645372 — intervention group
Group type: COMPARATOR
Intervention: Immediate cardioversion with biphasic shock
Number of subjects: 50
Study 14639195 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% dextrose
Number of subjects: 0
Study 14639195 — intervention group
Group type: COMPARATOR
Intervention: 30% glucose
Number of subjects: 0
Study 10522566 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymmetrical biphasic shock (6.5/2.5 ms)
Number of subjects: 19
Study 10522566 — intervention group
Group type: COMPARATOR
Intervention: Symmetrical biphasic shock (3.0/3.0 ms)
Number of subjects: 19
Study 7540892 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron
Number of subjects: 0
Study 7540892 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1951408 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ciprofloxacin 750 mg taken twice daily (n = 52)
Number of subjects: 105
Study 1951408 — intervention group
Group type: COMPARATOR
Intervention: Continued parenteral antibiotics (n = 53)
Number of subjects: 105
Study 6970265 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemoccult
Number of subjects: 448
Study 6970265 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemastix
Number of subjects: 448
Study 31368793 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized participants (n=25)
Number of subjects: 51
Study 31368793 — intervention group
Group type: COMPARATOR
Intervention: Eligible individuals who declined to enroll (n=26)
Number of subjects: 51
Study 27840104 — intervention group
Group type: EXPERIMENTAL
Intervention: High-power pose
Number of subjects: 247
Study 27840104 — intervention group
Group type: COMPARATOR
Intervention: Neutral or low-power poses
Number of subjects: 247
Study 25825336 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flux dialysis
Number of subjects: 155
Study 25825336 — intervention group
Group type: COMPARATOR
Intervention: Low-flux dialysis
Number of subjects: 155
Study 24374975 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat meal
Number of subjects: 15
Study 24374975 — intervention group
Group type: COMPARATOR
Intervention: Single-dose vemurafenib (960 mg)
Number of subjects: 15
Study 22892064 — intervention group
Group type: EXPERIMENTAL
Intervention: MBCP-FS
Number of subjects: 96
Study 22892064 — intervention group
Group type: COMPARATOR
Intervention: Autologous bone (mixed with Bio-Oss)
Number of subjects: 96
Study 19574322 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led comprehensive geriatric evaluation and management (GEM) programme
Number of subjects: 110
Study 19574322 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 110
Study 17726081 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg
Number of subjects: 626
Study 17726081 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg
Number of subjects: 626
Study 17726081 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg
Number of subjects: 626
Study 17726081 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg
Number of subjects: 626
Study 17726081 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 626
Study 15264650 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrosurgery
Number of subjects: 22
Study 15264650 — intervention group
Group type: COMPARATOR
Intervention: Conventional surgery
Number of subjects: 22
Study 11216961 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported periodontal disease
Number of subjects: 22037
Study 9735884 — intervention group
Group type: EXPERIMENTAL
Intervention: Forearm capillary filtration coefficient (group A)
Number of subjects: 22
Study 9735884 — intervention group
Group type: COMPARATOR
Intervention: Calf capillary filtration coefficient (group A)
Number of subjects: 22
Study 9735884 — intervention group
Group type: EXPERIMENTAL
Intervention: Forearm capillary filtration coefficient (group B)
Number of subjects: 22
Study 9735884 — intervention group
Group type: COMPARATOR
Intervention: Calf capillary filtration coefficient (group B)
Number of subjects: 22
Study 9208293 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumatic pedal compression
Number of subjects: 30
Study 9208293 — intervention group
Group type: COMPARATOR
Intervention: Control (posterior splint, ice, and elevation)
Number of subjects: 30
Study 2007745 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride 5 mg t.i.d. for 12 weeks
Number of subjects: 69
Study 2007745 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 6122970 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-monthly rifampicin (1,200 mg in a single oral dose) plus daily dapsone (50 mg/day)
Number of subjects: 93
Study 6122970 — intervention group
Group type: COMPARATOR
Intervention: Daily rifampicin (450 mg/day) plus daily dapsone (50 mg/day)
Number of subjects: 93
Study 6122970 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-monthly rifampicin (1,200 mg in a single oral dose)
Number of subjects: 93
Study 6122970 — intervention group
Group type: COMPARATOR
Intervention: Daily rifampicin (450 mg/day)
Number of subjects: 93
Study 31330810 — intervention group
Group type: EXPERIMENTAL
Intervention: Starch‐ and sucrose‐reduced diet (SSRD) for 4 weeks
Number of subjects: 105
Study 31330810 — intervention group
Group type: COMPARATOR
Intervention: Ordinary eating habits (control group)
Number of subjects: 105
Study 28867126 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Ventricular Tachycardia/Ventricular Fibrillation (VT/VF)
Number of subjects: 3602
Study 28867126 — intervention group
Group type: COMPARATOR
Intervention: No Early Ventricular Tachycardia/Ventricular Fibrillation (VT/VF)
Number of subjects: 3602
Study 25297492 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic partial nephrectomy (LPN)
Number of subjects: 280
Study 23702209 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative Stepped Care (CSC)
Number of subjects: 115
Study 23702209 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Usual Care (EUC)
Number of subjects: 115
Study 21514398 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimosiamose (10 mg bid)
Number of subjects: 18
Study 21514398 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 18461895 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine
Number of subjects: 954
Study 18461895 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 954
Study 16921033 — intervention group
Group type: EXPERIMENTAL
Intervention: Early thoracic radiotherapy (TRT) administered concurrently in the second cycle
Number of subjects: 325
Study 16921033 — intervention group
Group type: COMPARATOR
Intervention: Late thoracic radiotherapy (TRT) administered concurrently with the sixth cycle
Number of subjects: 325
Study 12835516 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy (doxorubicin + DES)
Number of subjects: 162
Study 12835516 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin alone
Number of subjects: 162
Study 10870148 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterolateral fusion with or without transpedicular fixation
Number of subjects: 111
Study 10870148 — intervention group
Group type: COMPARATOR
Intervention: Exercise program
Number of subjects: 111
Study 8878218 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 micrograms Engerix-B vaccine
Number of subjects: 193
Study 8878218 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 micrograms Engerix-B vaccine
Number of subjects: 193
Study 2059673 — intervention group
Group type: EXPERIMENTAL
Intervention: Olsalazine (OLZ) tablets (1g)
Number of subjects: 9
Study 2059673 — intervention group
Group type: COMPARATOR
Intervention: Olsalazine (OLZ) capsules (1g)
Number of subjects: 9
Study 6366141 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating combination chemotherapy (vincristine, doxorubicin, alkylating agents, and prednisone)
Number of subjects: 237
Study 6366141 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating combination chemotherapy
Number of subjects: 237
Study 6366141 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance chemotherapy with levamisole
Number of subjects: 237
Study 6366141 — intervention group
Group type: COMPARATOR
Intervention: Conventional chemotherapy (melphalan and prednisone)
Number of subjects: 237
Study 31886629 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 million ASCs plus intralesional fibrin glue (group A)
Number of subjects: 57
Study 31886629 — intervention group
Group type: COMPARATOR
Intervention: Intralesional fibrin glue (group B)
Number of subjects: 57
Study 30669280 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D₃ (1000 IU/day from 14 weeks gestation)
Number of subjects: 195
Study 30669280 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 195
Study 29459021 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesh repair
Number of subjects: 300
Study 29459021 — intervention group
Group type: COMPARATOR
Intervention: Suture repair
Number of subjects: 300
Study 26417061 — intervention group
Group type: EXPERIMENTAL
Intervention: 90-day use of Vaughan Williams class I or III antiarrhythmic drugs (AAD)
Number of subjects: 2038
Study 26417061 — intervention group
Group type: COMPARATOR
Intervention: Control group (no AAD)
Number of subjects: 2038
Study 24614387 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (4000 IU/day of vitamin D3 plus a daily multivitamin containing 400 IU of vitamin D3)
Number of subjects: 0
Study 24614387 — intervention group
Group type: COMPARATOR
Intervention: Placebo (placebo plus a multivitamin containing 400 IU of vitamin D3)
Number of subjects: 0
Study 24614387 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 0
Study 24614387 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21410548 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (INT): Educational intervention on hydration, including a lecture on hydration and improved water accessibility during training, dining, and resting areas.
Number of subjects: 92
Study 21410548 — intervention group
Group type: COMPARATOR
Intervention: Control (CON): No specific intervention, free access to fluids.
Number of subjects: 92
Study 19175929 — intervention group
Group type: EXPERIMENTAL
Intervention: AVI-014 at 4 mcg/kg
Number of subjects: 24
Study 19175929 — intervention group
Group type: EXPERIMENTAL
Intervention: AVI-014 at 8 mcg/kg
Number of subjects: 24
Study 19175929 — intervention group
Group type: EXPERIMENTAL
Intervention: AVI-014
Number of subjects: 24
Study 19175929 — intervention group
Group type: COMPARATOR
Intervention: filgrastim (Neupogen, Amgen) at 4 mcg/kg
Number of subjects: 24
Study 19175929 — intervention group
Group type: COMPARATOR
Intervention: filgrastim (Neupogen, Amgen) at 8 mcg/kg
Number of subjects: 24
Study 17984247 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutamide-metformin (62.5 mg/day + 850 mg/day)
Number of subjects: 32
Study 17984247 — intervention group
Group type: COMPARATOR
Intervention: Metformin alone (850 mg/day)
Number of subjects: 32
Study 15320689 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIIT)
Number of subjects: 22
Study 15320689 — intervention group
Group type: COMPARATOR
Intervention: Control period
Number of subjects: 22
Study 12392863 — intervention group
Group type: COMPARATOR
Intervention: Intervention not specified
Number of subjects: 0
Study 12392863 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9524012 — intervention group
Group type: EXPERIMENTAL
Intervention: Flecainide
Number of subjects: 22
Study 9524012 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilsicainide
Number of subjects: 22
Study 8887604 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 100 microg administered twice a day via a Diskhaler for 3 months
Number of subjects: 34
Study 8887604 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 2818824 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended massage (60 seconds)
Number of subjects: 20
Study 2818824 — intervention group
Group type: COMPARATOR
Intervention: Standard massage (30 seconds)
Number of subjects: 20
Study 1158630 — intervention group
Group type: EXPERIMENTAL
Intervention: Marijuana
Number of subjects: 0
Study 1158630 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30887960 — intervention group
Group type: EXPERIMENTAL
Intervention: Real acupuncture
Number of subjects: 30
Study 30887960 — intervention group
Group type: COMPARATOR
Intervention: Placebo (mock acupuncture)
Number of subjects: 30
Study 28623628 — intervention group
Group type: EXPERIMENTAL
Intervention: Software-based preference assessment in addition to the brochure about prostate cancer treatment
Number of subjects: 122
Study 28623628 — intervention group
Group type: COMPARATOR
Intervention: Education with a brochure about prostate cancer treatment
Number of subjects: 122
Study 25487185 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of toluidine blue with micropipette followed by 630-nm GaAlAs laser (power density: 10 mW/cm²) during two visits
Number of subjects: 25
Study 25487185 — intervention group
Group type: COMPARATOR
Intervention: Mouthwash diluted with dexamethasone (tab 0/5 in 5 ml water) for 5 min, followed by rinsing with nystatin 100,000 units for 5 min
Number of subjects: 25
Study 24010987 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% prilocaine plain, 5 mg/kg
Number of subjects: 90
Study 24010987 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine with 1:100,000 epinephrine, 2.5 mg/kg
Number of subjects: 90
Study 24010987 — intervention group
Group type: COMPARATOR
Intervention: No local anesthetic
Number of subjects: 90
Study 21396408 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal trivalent live attenuated influenza vaccine (LAIV)
Number of subjects: 99
Study 21396408 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular trivalent inactivated vaccine (TIV)
Number of subjects: 99
Study 21396408 — intervention group
Group type: EXPERIMENTAL
Intervention: Family history of asthma
Number of subjects: 99
Study 21396408 — intervention group
Group type: EXPERIMENTAL
Intervention: Genome-wide association study (GWAS)
Number of subjects: 99
Study 19302559 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide plus dexamethasone at first relapse
Number of subjects: 0
Study 16485884 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzoyl peroxide 5%/clindamycin phosphate 1% gel with dimethicone and glycerin
Number of subjects: 0
Study 16485884 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination use with topical retinoid
Number of subjects: 0
Study 15465745 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% portion size served
Number of subjects: 0
Study 15465745 — intervention group
Group type: EXPERIMENTAL
Intervention: 125% portion size served
Number of subjects: 0
Study 15465745 — intervention group
Group type: EXPERIMENTAL
Intervention: 150% portion size served
Number of subjects: 0
Study 15465745 — intervention group
Group type: COMPARATOR
Intervention: Control group (previous week's consumption)
Number of subjects: 0
Study 11534890 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (100 microg or 400 microg) twice daily plus formoterol 9 microg twice daily
Number of subjects: 0
Study 11534890 — intervention group
Group type: COMPARATOR
Intervention: Budesonide (100 microg or 400 microg) twice daily
Number of subjects: 0
Study 9324366 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 ml of prilocaine 1%
Number of subjects: 90
Study 9324366 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 ml of prilocaine 1% plus 10 ml bupivacaine 0.5%
Number of subjects: 90
Study 9324366 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 ml of prilocaine 1% plus 20 ml bupivacaine 0.5%
Number of subjects: 90
Study 8233733 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver nitrate eye prophylaxis
Number of subjects: 630
Study 8233733 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin eye prophylaxis
Number of subjects: 630
Study 8233733 — intervention group
Group type: COMPARATOR
Intervention: No eye prophylaxis
Number of subjects: 630
Study 2881572 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg ethyl loflazepate
Number of subjects: 12
Study 2881572 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg ethyl loflazepate
Number of subjects: 12
Study 2881572 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 29710111 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic cross‐checking between emergency physicians, 3 times a day
Number of subjects: 1680
Study 29710111 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 1680
Study 27151508 — intervention group
Group type: EXPERIMENTAL
Intervention: Diesel exhaust (DE) exposure for 2 hours
Number of subjects: 17
Study 27151508 — intervention group
Group type: COMPARATOR
Intervention: Filtered air (FA) exposure for 2 hours (control)
Number of subjects: 17
Study 27151508 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-exposure to DE and allergen
Number of subjects: 17
Study 24112602 — intervention group
Group type: COMPARATOR
Intervention: US-BT1 brachytherapy technique
Number of subjects: 0
Study 24112602 — intervention group
Group type: COMPARATOR
Intervention: US-BT2 brachytherapy technique
Number of subjects: 0
Study 22390720 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate second resection of the tumor bed after complete TUR
Number of subjects: 126
Study 22390720 — intervention group
Group type: COMPARATOR
Intervention: No immediate second resection of the tumor bed
Number of subjects: 126
Study 20805273 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg
Number of subjects: 26
Study 20805273 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin 40 mg
Number of subjects: 26
Study 18579510 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg mifepristone every other day for 3 months
Number of subjects: 30
Study 18579510 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30